The European Association of Nuclear Medicine (EANM) said it has changed the name of the Translational Molecular Imaging Committee to the Translational Molecular Imaging & Therapy Committee (C-TMI&T).
Because many radiopharmaceuticals in nuclear medicine can be applied as theranostics, the association's thinking went, a single committee, i.e., C-TMI&T, can apply to preclinical and translational imaging as well as therapy studies.
C-TMI&T brings together the disciplines related to basic and translational research in molecular imaging and therapy in order to offer expertise and education to the nuclear medicine community in the translation of research into clinical applications, EANM said.
